HEALTHSTORY 741· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 740Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 742 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

08HEALTH

FDA clears first CELMoD drug for blood cancer as a $6.7 billion shareholder lawsuit returns to court

Multiple myeloma, a blood cancer, now has a new oral treatment approved by U.S. regulators. The Food and Drug Administration cleared Zenbexus, made by Bristol Myers Squibb, as the first drug in a new class called CELMoDs and the first drug…

health2 MIN

46HEALTH

Autoimmune research pioneer Georg Schett co-founds his first biotech, choosing antibody therapies over CAR-T

Georg Schett, the German scientist who spent five years demonstrating that CAR-T therapy, a treatment that engineers a patient's own immune cells to target and eliminate the source of disease, can reset the immune system in autoimmune…

health2 MIN

62HEALTH

Splitting the MMR vaccine risks more missed doses and more sick children, history suggests

Separating the MMR vaccine into individual shots is likely to produce more missed doses and more sick kids. The MMR is a single injection covering measles, mumps, and rubella. It is now the target of a White House executive order

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk